82 CHAPTER 2.2 Table SI1.1. Continued. STOPP Action Clarity rating Condition Clarity rating Explanation Clarity rating C8 Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors 67% for first deep venous thrombosis without continuing provoking risk factors (e.g. thrombophilia) for > 6 months, 67% (no proven added benefit). 83% C9 Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors 67% for first pulmonary embolus without continuing provoking risk factors (e.g. thrombophilia) for > 12 months 67% (no proven added benefit). 83% C10 NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors 67% in combination 67% (risk of gastrointestinal bleeding). 67% C11 NSAID 67% with concurrent antiplatelet agent(s) without PPI prophylaxis 67% (increased risk of peptic ulcer disease) 67% D D1 Tricyclic Antidepressants (TCAs) 67% with dementia, narrow angle glaucoma, cardiac conduction abnormalities, prostatism, or prior history of urinary retention 33% (risk of worsening these conditions). 50%
RkJQdWJsaXNoZXIy MTk4NDMw